Tibotec Pharma Says TMC278 Phase 3 Trials Achieve Primary Objective

Tibotec Pharma says TMC278 phase 3 trials achieve primary objective
Tibotec Pharmaceuticals announced results from two pivotal phase-3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.
Read more on PharmaBiz

VA to allow patients to use medical marijuana
The Department of Veterans Affairs will formally allow patients treated at its hospitals and clinics to use medical marijuana in states where it is legal, a policy clarification that veterans have sought for several years. A department directive, expected to take effect next week, resolves the conflict in veterans facilities between federal law, which outlaws marijuana, and the 14 states that …
Read more on News-Medical-Net

Life’s a beach for some homeless in Hawaii
Every morning, Tony Williams wakes to the sound of waves crashing on Hawaii’s famed Waikiki beaches and has a spectacular view of the Pacific. But he’s not paying a cent for his priceless vista.
Read more on AP via Yahoo! News